ac5b01377_si_001.pdf (781.26 kB)
Download fileQuantitative Host Cell Protein Analysis Using Two Dimensional Data Independent LC–MSE
journal contribution
posted on 2015-09-15, 00:00 authored by Amy Farrell, Stefan Mittermayr, Brian Morrissey, Niaobh Mc Loughlin, Natalia Navas Iglesias, Ian W. Marison, Jonathan BonesHost cell proteins (HCPs) are bioprocess-related
impurities arising
from cell-death or secretion from nonhuman cells used for recombinant
protein production. Clearance of HCPs through downstream purification
(DSP) is required to produce safe and efficacious therapeutic proteins.
While traditionally measured using anti-HCP ELISA, more in-depth approaches
for HCP characterization may ensure that risks to patients from HCPs
are adequately assessed. Mass spectrometry methods provide rationale
for targeted removal strategies through the provision of both qualitative
and quantitative HCP information. A high pH, low pH, reversed-phase
data independent 2D-LC–MSE proteomic platform was
applied to determine HCP repertoires in the Protein A purified monoclonal
antibody (mAb) samples as a function of culture harvest time, elution
buffer used for DSP and also following inclusion of additional DSP
steps. Critical quality attributes (CQAs) were examined for mAbs purified
with different Protein A elution buffers to ensure that the selected
buffers not only minimized the HCP profile but also exhibited no adverse
effect on product quality. Results indicated that an arginine based
Protein A elution buffer minimized the levels of HCPs identified and
quantified in a purified mAb sample and also demonstrated no impact
on product CQAs. It was also observed that mAbs harvested at later
stages of cell culture contained higher concentrations of HCPs but
that these were successfully removed by the addition of DSP steps
complementary to Protein A purification. Taken together, our results
showed how mass spectrometry based methods for HCP determination in
conjunction with careful consideration of processing parameters such
as harvest time, Protein A elution buffers, and subsequent DSP steps
can reduce the HCP repertoire of therapeutic mAbs.